GNRH1 and cancer: Since most drugs fail during phase III clinical trials due to efficacy issues and toxicity23, there is a crucial need to study the possible toxicity that is associated with LHRH-conjugated cancer drugs such as LHRH-paclitaxel and LHRH-prodigiosin.